In consideration of the ever-growing obesity global epidemic, insulin resistance and hyperinsulinemia, closely interrelated with obesity, are receiving increasing attention and new experimental antineoplastic drugs—targeting IGF-1 and/or insulin signaling pathways—are being employed in clinical trials (31). Here, IGF1 is linked to Insulin resistance.